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1 Unidade de Xenética, Departamento de Anatomı́a Patolóxica e Ciencias Forenses, and Instituto de Ciencias Forenses, Grupo de Medicina Xenómica (GMX), Facultade de
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Abstract
Background: Mitochondrial DNA (mtDNA) variation (i.e. haplogroups) has been analyzed in regards to a number of
multifactorial diseases. The statistical power of a case-control study determines the a priori probability to reject the null
hypothesis of homogeneity between cases and controls.
Methods/Principal Findings: We critically review previous approaches to the estimation of the statistical power based on
the restricted scenario where the number of cases equals the number of controls, and propose a methodology that
broadens procedures to more general situations. We developed statistical procedures that consider different disease
scenarios, variable sample sizes in cases and controls, and variable number of haplogroups and effect sizes. The results
indicate that the statistical power of a particular study can improve substantially by increasing the number of controls with
respect to cases. In the opposite direction, the power decreases substantially when testing a growing number of
haplogroups. We developed mitPower (http://bioinformatics.cesga.es/mitpower/), a web-based interface that implements
the new statistical procedures and allows for the computation of the a priori statistical power in variable scenarios of case-
control study designs, or e.g. the number of controls needed to reach fixed effect sizes.
Conclusions/Significance: The present study provides with statistical procedures for the computation of statistical power in
common as well as complex case-control study designs involving 26k tables, with special application (but not exclusive) to
mtDNA studies. In order to reach a wide range of researchers, we also provide a friendly web-based tool – mitPower – that
can be used in both retrospective and prospective case-control disease studies.
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Introduction
The mitochondrion produces most of the ATP in the cell, an
energy source on which almost all physicochemical processes
depend. Each cell contains dozens or hundreds of mtDNA
genomes that are inherited as a single haplotypic block from the
mother to the offspring. Germ-line mutations accumulate on top
of existing haplotypes, and these haplotypes aggregate in human
populations according to their demographic histories. Due to the
particularities of the mtDNA molecule (i.e. matrilineal inheritance
and lack of recombination [1]), it is straightforward to reconstruct
phylogenetic relationships between human haplotypes [2–4].
Phylogenetically related haplotypes in the population are com-
monly grouped into clusters or haplogroups [5]. Thus, hap-
logroups represent branches of the mtDNA phylogeny, and the set
of diagnostic variants defining these clades are popularly known as
the sequence motif [6,7]. Screening for these variants in a given
mtDNA molecule can provide sufficient information to allocate a
particular mtDNA genome into a given haplogroup [8–10].
In the last few years, a huge number of studies have been
conducted addressing the presumable association of mtDNA
haplogroups with different complex diseases, including cancer
[11,12], Alzheimer [13,14], Parkinson [15–17], schizophrenia
[18–21], infectious diseases [22,23], diabetes [24], LHON [25],
etc. Most of these disease studies are population-based, that
means, the mtDNA variability is compared between cohorts of
cases and representative healthy control (case-control studies),
where the statistically significant over-representation of a given
variant in cases regarding controls might point to a biological
association of this variant with the disease.
Statistical procedures are important in order to understand the
presumable relationship between mtDNA haplogroups and
diseases. Estimating a priori statistical power is fundamental in
case-control association studies given that this is the way to
evaluate to what extent a positive finding is likely to be not at
random. However, case-control association studies targeting the
mtDNA variation [22] rarely compute power mainly due to the
lack of the statistical procedures that are necessarily different to
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those employed using autosomal DNA markers. To the best of our
knowledge, only Samuels et al. [26] investigated the issue of
statistical power in regards to cases-control mtDNA studies
involving 26k. These authors used a simulation-based permuta-
tion test (Monte-Carlo) in order to estimate power calculations for
prospective case-control studies. According to these authors, very
large cohorts are needed to reliably detect and association between
mtDNA haplogroups and complex diseases. This study however
only deals with the restricted scenario where the number of cases
equals the number of controls. The particular biological applica-
tion of Sánchez et al. [27] on a mtDNA case has to do specifically
with 263 tables, comparing a RFLP polymorphism (binary) and
the three genotypes derived from a biallelic albumin marker.
Several software packages and statistical procedures were
designed for the calculation of statistical power and sample size.
Most of the procedures developed to date can only deal with 262
tables (the great majority) or 263 tables [27] (Table S1). Thus,
most of the software packages have been designed for the
estimation of power or/and sample size in the most common
scenario involving allele frequencies deriving from autosomal
binary markers (SNPs), that is, involving allele or genotype
association tests. Only two software packages, namely G*Power 3
[28] and Pass 12 [29], are able to treat tables r6k; however, these
two packages only deal with scenarios where the number of cases
equals number of controls. Finally, osDesign [30] is based on
logistic regression, and although it can deal with r6k tables it does
not allow estimating samples sizes.
In the present study we consider more general case-control
disease scenarios involving any number of cases and controls and
26k tables. For instance, it is a common situation that only a
limited number of patients can be recruited in a particular study;
however, an increase in the number of controls could contribute to
reach a reasonable statistical power. The model elaborated in the
present study is based on simulations (Monte Carlo method) as a
way to estimate the statistical power in case-control studies where
there is interest in investigating the presumable relationship
between a certain disease and a number of mtDNA haplogroups
(or haplotypes or mtDNA SNPs [mtSNPs]). We consider the
frequency of the risky allele or haplogroup in controls (p0) and in
cases (p1), and the difference between these two parameters is
proportionally distributed to the frequencies of the remaining
allele or haplogroup categories in cases. In addition, a web-tool
named mitPower has been also developed to implement all the
statistical procedures developed in the present study.
Methods
Data simulation
We first build 26NH (in general, 26k) tables (10,000 simula-
tions), where NH denotes the number of haplogroups considered
(but could also be any number of haplotypes or mtSNPs). Two
multinomial samples are used to build the contingency tables,
taking as frequencies the estimated frequencies, and as size, the
number of controls and cases of our study. In the simulated tables
the row variable represents the status of case or control, while the
columns represent the allele variables or haplogroups into which
individuals are sorted. For the sake of simplicity, NH was set up to
11 (unless otherwise stated) but the method and mitPower has
been designed to accept any number of haplogroups. As done in
Samuels et al. [26], the following 11 haplogroup frequencies were
considered as example: H (41%), I (2%), J (11%), K (8%), M (1%),
T (13%), U (15%), V (13%), W (2%), X (2%) and a residual
haplogroup (2%).
The power values obtained using MitPower have been validated
with other tools (Table S1) in comparable scenarios that consider
262 tables and equal numbers of cases and controls. MitPower
was additionally validated for 263 tables with the procedure
shown by Sánchez et al. [27].
Statistical analysis
First, the computation of the probabilities of 262 contingency
tables is the best option to test the homogeneity of control and case
sample populations; however, the computational requirements
increase with the dimension of the contingency tables. A way to
overcome this problem is to implement a Fisher’s exact test that
estimates the probability of a contingency table using a Monte
Carlo simulation approach. On the other hand, the Chi-squared
statistic is computationally feasible for 26k tables being k any
entire positive number. Both tests yield very similar results
(Figure 1 and Figure S1) and both are implemented in Mit-
Power. From here onwards, we have used the Chi-square statistic,
which compares the values obtained in our contingency tables
against the values expected under the null hypothesis of
homogeneity.
First, we generate a number of tables 26NH under a given
hypothesis. A random number between 0 and 1 is generated using
the R function runif, and this number is used as the seed for
simulations. Power value estimators are obtained as the percentage
of simulated tables with P-value below a fixed significance level.
In order to obtain the P-value for each simulated table, the
distribution of our statistic has to be known. This distribution is
approached here using two alternative procedures: the asymptotic
and the permutation approach. The former approach is based on
the asymptotic distribution of the Chi-square statistics. Note that
some authors argued [31] that an increase of the false-positive rate
occurs when the Cochran’s rule is not verified; so the asymptotic
approximation should be considered acceptable when the
Cochran’s rule is verified [31]; that means that a contingency
table cannot contain expected values below one, and that no more
than 20% of the expected value can be below five. The
permutation method aims to overcome this problem. First, a
large number of permuted tables of our initial data (contingency
tables) are generated, with the only restriction that total sums by
rows and columns have to remain constant. For each of these
permutations, the Chi-square statistic is computed, and the P-
value is obtained as the proportion of permutations with a Chi-
square statistics higher than the statistics in the original data set
[32,33]. There are several ways to obtained permuted tables
[32,34,35], and we chosen the method provided by the function
chisq.test [36].
Theoretically, the asymptotic and the permutation approaches
should have similar values as the sample size increases [37]. Some
experiments have been done in this direction (Table 1, and see
text below) in order to corroborate this expectation. Along the
simulation experiments carried out in the present manuscript, the
permutation method was preferred given that it generally performs
better than the asymptotic one (see below).
All the computations were carried out in R (http://www.r-
project.org/), and using the functions chisq.test, fisher.test, and pchisq
of package stats.
mitPower: a web interface to estimate statistical power in
26k tables
mitPower is a web-based tool (http://bioinformatics.cesga.es/
mitpower/) that allows estimating the statistical power in case-
control association disease studies. Several other utilities are
available in mitPower such as the estimation of: (i) the a posteriori
Statistical Power in mtDNA Case-Control Studies
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statistical power, (ii) the sample size needed in order to reach a
given statistical power, and (iii) the minimum deviation from the
null hypothesis (of no association) detectable under a given
statistical power (expressed as OR and haplogroup frequency in
cases).
The software mitPower allows using two calibration methods:
the asymptotic and the permutation procedure. The permutation
procedure can be computationally demanding (see below) so the
asymptotic procedure might be more convenient for complex
scenarios.
Figure 1. Representation of power values for three haplogroups (H, J. and I) as a function of the number of cases and using the Chi-
square test (significance level a = 0.05). Colors indicate different deviations from the null hypothesis; thus, black represents a frequency in cases
100% higher than in controls, red represents an increment of 50%, and green an increment of 25% (with the difference distributed proportionally
between the remaining non-risky haplogroups). The different lines indicate different case-control odds. The continuous line denotes an odd control-
case of 1:1, the dotted line of 2:1, and the pointed line of 3:1. Frequencies in controls for each haplogroup are indicated above each plot. Note that
the results can be directly comparable with Samuels et al. [26] (see their Figure 1) when number of cases equals number of controls.
doi:10.1371/journal.pone.0073567.g001
Table 1. Estimates of statistical power (%) under the null hypothesis using the asymptotic distribution versus the permutation





distribution ElapsedTime Permutations(1,000) ElapsedTime Permutations(10,000)
Elapsed
Time
1,000 100 3.54 0.11 5.37 1.95 5.25 17.18
200 4.29 0.09 5.21 2.50 5.42 22.07
300 4.91 0.11 5.72 2.76 5.72 24.02
400 3.80 0.10 4.00 2.90 4.00 25.59
500 3.60 0.11 4.10 3.03 3.80 26.85
600 4.50 0.10 5.20 3.19 4.80 28.10
700 5.60 0.11 5.80 3.28 5.90 29.24
800 5.20 0.09 5.50 3.41 5.40 30.31
900 5.10 0.11 5.30 3.48 5.10 31.13
1000 4.10 0.10 4.20 3.77 4.10 32.21
10,000 100 3.25 0.93 4.92 20.28 4.78 175.74
200 4.00 1.13 4.78 33.21 4.81 280.80
300 4.72 1.00 5.20 28.14 5.10 273.57
400 4.72 1.32 4.68 30.00 4.74 290.17
500 4.75 1.26 5.08 49.77 5.06 314.36
600 4.73 1.03 4.98 32.15 4.93 312.73
700 5.04 1.33 5.26 33.69 5.30 334.70
800 5.27 1.23 5.57 50.14 5.41 330.14
900 4.95 1.34 5.04 35.72 5.18 349.69
1000 5.07 1.22 5.35 53.64 5.19 348.52
Estimates were computed for 1,000 and 10,000 simulated tables (ST), number of cases equal to number of controls, and level of significance a= 0.05 (therefore,
estimated power values should be close to 5%). Time estimates were obtained using an IntelH CoreTM I5 3.1 GHz. These values were averaged over ten simulations each.
doi:10.1371/journal.pone.0073567.t001
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The mitPower web interface is written in PHP, allowing users to
enter their inputs through an HTML form. All the mitPower
analyses are executed using R scripts (see above), which are called
from the interface through Rscript and run at the web server. Their
output is ultimately formatted for web display again by the PHP
interface. Results links are kept for 24 hours in the server.
The underlying R scripts in mitPower run on a web server
hosted by the Supercomputing Center of Galicia (CESGA; http://
www.cesga.es) located in Santiago de Compostela (Galicia, Spain).
Results and Discussion
Two procedures were followed to calibrate the distribution of
our statistic: the asymptotic and the permutation method. In order
to test which of the two approaches performs better, a simulation
experiment has been performed considering different sample sizes,
number of simulations, and permutations. The experiments
indicate that the permutation method performs better than the
asymptotic one given that power estimates approach closer to the
significant value under the null hypothesis for low sample sizes.
However, both approaches yield good estimates when considering
large sample sizes (Table 1). This is in agreement with theoretical
expectations given that for large samples, their statistical distribu-
tion should be equivalent, as the permutation distribution should
converge to the tabulated distribution [37].
The results indicate that (i) the permutation method tends to fit
better to the significance level than the asymptotic approach when
the null hypothesis is true (specially for low sample sizes), and (ii)
computational requirements using permutation can be an issue
when considering a large number of iterations (large sample sizes);
in such situations, the asymptotic calibration method might be
more convenient (Table 1).
As done in Samuels et al., we would assume that haplogroup
mtDNA frequencies in controls are known (note that there exist
hundred of human population studies carried out to a local,
regional or continental scale where these frequencies are available,
at least for the most common haplogroups). We then simulated
increases in the frequency of a risky haplogroup in cases, with the
differences distributed proportionally between the remaining
haplogroups (therefore, assuming there is no a priori assumption
of an association with any of the remaining haplogroups
considered) [26].
In agreement with Samuels et al.[26], we observed that power
strongly depends on sample sizes, haplogroup population frequen-
cies, and the deviation from the null hypothesis when using equal
numbers of cases and controls (see solid lines in Figure 1). We
next evaluate the situation where the number of cases differs from
the number of controls. As shown in Figure 1, statistical power
strongly depends on the case:control ratio when the other
parameters are fixed, but this dependence is not as simple. As
expected, power can increase very substantially as more controls
exist relative to the number of cases. For instance, the statistical
power to detect an association of haplogroup J increases from 60%
to 80% when doubling the number of controls respect to cases in
the example provided in Figure 1.
Samuels et al. [1] introduced the Nscaled parameter for the estimation
of the power. This parameter considers the difference between







being p0 the frequency of the risky haplogroup in controls, p1 the
frequency of the risky haplogroup in cases, and N the number of
cases and controls (the total sample size is 2N).
We further consider the more general situation where the











Nscaled and Nsc measures the squared standardized difference
between frequencies in cases and in controls for the risky
haplogroup. For 262 tables and a sample size large enough, the
Nscaled parameter follows a chi-square distribution with one degree
of freedom due to the asymptotic normality of the standardized
difference between frequencies [38].
As shown in Figure 2, there is a clear relationship between the
parameter Nsc and the power values. These values follow the
theoretical curve obtained for 262 tables and equal numbers of















Where p0 in the frequency in controls, p1is the frequency in
controls, N is the sample size for each arm and Zb and Z1{a=2
are
normal quantile for b and 1{a=2.Simulations also indicate that
the statistical power decreases as more haplotypes are tested
(Figure 3). Samuels et al. introduced a parameter, NH (number of
different haplogroups), that raised to the power of 0.37 allows to fit
the statistical power to a single theoretical curve. According to








Note that the value 0.37 seems to have been obtained
empirically by Samuels et al, (no specific formulae or indications
were given in this regard). In the analysis shown in Figure 4 we
aimed to reproduce their findings. The simulations corroborate
the fact that 0.37 is the value that allows to better fit the data to the
theoretical curve for values of statistical power above 50%. Below
50% an exponent of 0.5 would perform better although it can
assume that values of statistical power below 50% might be not
relevant in association studies. Therefore, we observed that NH
raised to the power of 0.37 allows fitting the statistical power to
those scenarios where the number of cases differs from the number
of controls (Figure 3).
Finally, Nsc allows to relate all the parameters involved in the












Samuels et al. (see A1 in their Appendix A) propose to use Nscaled
to estimate directly the statistical power and to determine the
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minimum number of controls and disease cases (NCmin) required for
a specific level of power (their formula (2)). However, this formula
applies when number of cases equals the number of controls. The
simulation method aims to overcome the limitation of this formula
allowing for different sample sizes in cases and controls.
We then adjusted the parameter NCmin for the more general
scenario involving unequal numbers of cases and controls. Two
Figure 2. On the left side are the power values (a = 0.05) as a function of the number of cases for different haplogroups (the circles
refer to haplogroup H, triangles to haplogroup J and crosses to haplogroup I). The intensity of the symbols indicate different odds ratio
control-case: the thinner symbols indicate odds 1:1, the medium symbols odds 2:1, while the bolded symbols odds 3:1. Colors indicate different
deviations from the null hypothesis; black: the frequency of the risky allele is 100% higher in cases than in controls, red: 50%; and green 25%. The
graph indicates that there is not a relationship between the number of cases and the statistical power value. On the right side are the power values as
a function of the statistic Nsc; in red is the theoretical curve for the statistical power for 262 tables when the number of controls is equal to the
number of cases.
doi:10.1371/journal.pone.0073567.g002
Figure 3. The left side shows power values (a = 0.05) as a function of Nsc without correction of number of haplogroups (NH) for
different number of haplogroups and when the number of cases equals the number of controls. The right side shows power corrected
according to NH, and the nonparametric estimated regression curve. Colored circles denote different number of haplogroups; black: 4 haplogroups;
red: 8 haplogroups; green: 12 haplogroups; dark blue: 16; and light blue: 20. Haplogroup frequencies were built using a vector of probabilities where
the risk allele takes values 0.30, 0.15 or 0.05 (other values led to the same results; data not shown). The risky haplogroup take relative frequency
differences in cases with respect to control of 100%, 50% and 25%. The number of cases takes values of 100, 250, 500, 750 and 1000, and control-case
odds of 1, 2 and 3. We noted that other values do not change the distribution. The red line indicates the theoretical curve for 262 tables and equal
numbers of cases and controls, while the black line is the non-parametric estimator of regression between Nsc parameter and the statistical power.
doi:10.1371/journal.pone.0073567.g003
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options are possible: (i) estimation of the sample size given a
control-case ratio; or (ii) estimation of the minimum number of
controls (cases) when the number of cases (controls) is fixed.
In the first situation, if N denotes the number of cases, a the
control-case ratio, and hN the number of controls, the minimum
number of cases needed to reach a power b with a significance














where Nabsc denotes the Nsc value providing a desired power b and
a significance level a, while [?] denotes the integer part function.
The number of controls can be estimated as hNab. Note that a
value of h~1would reproduce the particular scenario considered
by Samuels et al. [26].
In the second situation, the minimum number of controls




significance level a and a powerb, can also be estimated when
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where Nabsc is the value providing the power desired a for a
significance level b, and [?] denotes the integer part function. This
allows estimating the number of controls (number of cases) needed
to reach a required power given a number of cases (number of
controls). Note that statistical power is limited by the restrictions in
equations (7) and (8); this is the reason of why power becomes
stationary when the number of controls increases in regards to the
number of cases (Figure 1).
It is also worthwhile to estimate the minimum deviation of the
null hypothesis that can be detected for a power value b and a
Figure 4. The simulations show that the parameter NH raised to the power of 0.37 is the one that empirically allows a better fit of
the data to the theoretical curve of statistical power even in scenarios where the number of cases differs from the number of
controls. See legend of Figure 3 for more information on the simulation.
doi:10.1371/journal.pone.0073567.g004
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significance level a (Dabmin), assuming we know haplogroup
frequencies in controls and considering a given number of cases





deviation of null hypothesis. Note that it must verify 0vp1v1. If























































Where ORmin denotes the minimum OR that can be detected for a
power value b and a significance level a.
The applications above require knowledge of the Nabsc value
given a significance level a and a power b. This parameter can be
obtained by way of simulations and nonparametric regression
(Figure 3 [right] shows the scenario wherea~0:05). Note that
nonparametric regression seems to perform well for power values
above 60%. The package sm [40] implements local linear
estimation, window-selector cross validation and Gaussian kernel,
that allows to obtain Nsc values for different significance levels a
and power values. These values can be used in equations (6)–(10)
in order to estimate the desired parameters (as done in Table 2).
The same simulation methods proposed to compute a priori
statistical power can be applied for the estimation of the a posteriori
power. Note however, that we treat a posteriori power in a different
context as interpreted by others [41,42]. Our procedure involves
generating new data (tables) using the sample proportions and
sample sizes obtained from a particular study. Therefore, the null
hypothesis is tested by simulating new contingency tables. The
procedures are analogs to the ones used to compute the a priori
power.
Computation of the statistical power is essential to anticipate if
the positive findings obtained in case-control disease studies are
reliable. The present study has been motivated by the fact that the
only available procedures to date to compute statistical power in
mtDNA association studies [26] only allows to deal with scenarios
involving 262 tables (or 263 tables), or if 26k tables only study
designs considering equal numbers of cases and controls (which
does not represent the most common scenario in association
studies). In the present study, we also provide with a web interface
that implements the procedures developed in the present study
(mitPower).
Conclusions
During the last decade, a large number of mtDNA case-control
studies have been published in the literature, most of them
pointing to a number of haplogroups presumably associated with a
complex disease. The validity of many of these conclusions might
be questionable, given that most of them are underpowered. Most
of these studies did not estimate the a priori statistical power
because statistical tools were not available at the time.
The procedures developed in the present study allow the
computation of statistical power in common as well as complex case-
control study designs involving 26k. The results indicate that
underpowered studies could reach reasonable power by increasing
the number of controls and reducing the number of hypothesis testing
(i.e. haplogroups). In order to reach a wide range of researchers, we
provide a friendly web-based tool (mitPower) that implements all the
statistical procedures developed in the present study; this software can
be used in both retrospective and prospective case-control disease
studies. Note that the term retrospective is considered here as done
before: ‘‘the prospective power that can be obtained ignoring the fact that data have
been gathered and a hypothesis has been tested. In essence, it computes the prospective
power of the test as if: (a) the study and analyses had not yet been conducted and (b)
the sample effect size is the hypothesized population effect size’’ [43]. Further
developments of mitPower could involve the implementation of
multiple test corrections for the computation of the statistical power (in
the sense as it was suggested before in 262 tables [44]) and in two-stage
case-control designs [45]. Also challenging would be to explore the
phylogenetic relationship existing between different haplogroups (the
phylogenetic dependence) or mtSNPs and how this dependence could
influence the estimation of power. Finally, other statistical/computa-
tional approaches could find their place in 26k tables, such as the use of
Markov Chain Monte Carlo methods (MCMC), already explored for
26262 tables [46].
Supporting Information
Figure S1 Representation of power values for three
haplogroups (H, J. and I) as a function of the number of
cases and using the Fisher’s exact test instead of the Chi-
square test (Figure 1)(significance level of a = 0.05).
Colors indicate different deviations from the null hypothesis; thus,
black represents a frequency in cases 100% higher than in
controls, red represents an increment of 50%, and green an
increment of 25% (with the difference distributed proportionally
between the remaining non-risky haplogroups). The different lines
indicate different case-control odds. The continuous line denotes
an odd control-case of 1:1, the dotted line of 2:1, and the pointed
line of 3:1. Frequencies in controls for each haplogroup are
indicated above each plot.
(TIF)
Table 2. Nabsc estimates for a significance level a and a power
value b using non-parametric regression.
b\a 10% 5% 1% 0.5% 0.1%
95% 11.61 13.79 18.68 19.84 21.33
90% 6.87 8.12 10.91 12.03 15.37
85% 5.97 7.07 9.47 10.64 13.77
80% 5.29 6.35 8.50 9.55 12.42
75% 4.59 5.80 8.05 8.86 11.42
70% 4.17 5.30 7.44 8.18 10.83
65% 3.72 4.68 6.82 7.84 10.15
60% 3.26 4.28 6.36 7.28 9.49
55% 2.96 3.88 5.96 6.75 9.79
50% 2.62 3.50 5.61 6.71 8.27
These values were averaged over ten simulations each. Note that these values
differ slightly from those obtained by Samuels et al. (see their Table 3) [26] due
to the simulation procedure implemented in both studies and because we
consider unequal number of cases and controls.
doi:10.1371/journal.pone.0073567.t002
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Table S1 Comparison of different software packages
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